• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Diabetic kidney disease has a high global disease burden and substantially increases the
risk of kidney failure and cardiovascular events. Despite treatment, there is substantial …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

Chronic kidney disease (CKD) is defined by a low glomerular filtration rate or high
albuminuria, and affects 15–20% of adults globally. CKD increases the risk of various …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under
development for the treatment of type 2 diabetes (T2D) and obesity. Its association with …

Background According to current consensus guidelines for type 2 diabetes management,
bodyweight management is as important as attaining glycaemic targets. Retatrutide, a single …

Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2
diabetes mellitus (T2DM), particularly in low-and middle-income countries. To effectively …

Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …